BrainsWay (NASDAQ:BWAY) Stock Rating Reaffirmed by HC Wainwright

HC Wainwright restated their buy rating on shares of BrainsWay (NASDAQ:BWAY) in a research report sent to investors on Monday morning, Benzinga reports. HC Wainwright currently has a $16.00 price objective on the stock.

Separately, Northland Securities raised their price objective on BrainsWay from $11.00 to $12.50 and gave the stock an “outperform” rating in a research report on Thursday, October 3rd.

BrainsWay Stock Down 1.2 %

Shares of BWAY opened at $9.94 on Monday. BrainsWay has a 52-week low of $3.09 and a 52-week high of $10.61. The company has a market capitalization of $165.65 million, a PE ratio of -110.44 and a beta of 1.26. The stock has a fifty day simple moving average of $8.42 and a two-hundred day simple moving average of $6.87.

BrainsWay (NASDAQ:BWAY) last issued its quarterly earnings data on Tuesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter. The firm had revenue of $10.01 million during the quarter, compared to the consensus estimate of $9.40 million. BrainsWay had a return on equity of 1.45% and a net margin of 1.67%. During the same period last year, the company earned ($0.05) EPS. As a group, equities analysts anticipate that BrainsWay will post 0.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BrainsWay

Several institutional investors have recently bought and sold shares of BWAY. Good Life Advisors LLC boosted its stake in shares of BrainsWay by 65.5% in the 3rd quarter. Good Life Advisors LLC now owns 55,800 shares of the company’s stock valued at $516,000 after buying an additional 22,080 shares during the period. Perritt Capital Management Inc purchased a new position in shares of BrainsWay in the 2nd quarter valued at about $121,000. Acadian Asset Management LLC boosted its stake in shares of BrainsWay by 48.1% in the 2nd quarter. Acadian Asset Management LLC now owns 259,787 shares of the company’s stock valued at $1,567,000 after buying an additional 84,371 shares during the period. Rhumbline Advisers boosted its stake in shares of BrainsWay by 10.3% in the 2nd quarter. Rhumbline Advisers now owns 18,077 shares of the company’s stock valued at $110,000 after buying an additional 1,695 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of BrainsWay in the 1st quarter valued at about $60,000. 30.11% of the stock is owned by institutional investors and hedge funds.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases.